Fair Value Calculator Fair Value Calculator
EN DE

RHT (RHT) Fair Value & Analysis

Healthcare · Market cap A$19.1M

R RHT RHT · AU
PriceA$0.0460
Fair ValueA$0.0340
Upside-26.0%
Quality51/100
Watch RHT for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range A$0.0294 – A$0.0386

Fair value as of: Jun 26, 2026

From 9 valuation models · updated 6 days ago

Fair value updated Jun 26, 2026 — revised from A$0.0200 to A$0.0340 (+70.2%) since Jun 25, 2026. Share price +9.8% over the past month.

Price vs Fair Value (12 months)

A$0.0562 A$0.0337 Fair Value A$0.0340 Jun 2025 Jul 2026

12‑month range A$0.0337 – A$0.0562 · fair‑value band A$0.0294 – A$0.0386 · the A$0.0460 price screens above the A$0.0340 fair value. As of Jun 26, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

RHT (RHT) currently trades at A$0.0460, while our model-based Fair Value estimate is A$0.0340 — implying the stock looks roughly 26.0% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, RHT generated revenue of A$13.8M at a net margin of 5.6%. Revenue grew 53.1% year over year. It earns a return on equity of 7.3%. Fundamentals as of Jun 26, 2026

Key figures & financial health

Revenue (TTM) A$13.8M
Revenue growth (YoY) +53.1%
Net margin 5.6%
Return on equity 7.3%
Free cash flow A$805K FY2025
Operating margin 15.6%
More key figures
EPS growth (YoY) +5.7%
Net debt A$826K FY2025

Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

RHT reported revenue of A$11.1M in FY2025 versus A$3.8M in FY2021, a compound +30.8%/yr. Reported net income was −A$1.7M in FY2025.

Revenue +30.8%/yr
FY21 A$3.8M
FY22 A$3.8M
FY23 A$4.4M
FY24 A$8.6M
FY25 A$11.1M
Net income
FY21 A$586K
FY22 −A$1.1M
FY23 −A$780K
FY24 A$169K
FY25 −A$1.7M

Is RHT fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $163.76 $103.58 -37%
Pro Medicus Limited PME A$172.80 A$32.25 -81%
BrightSpring Health Services, Inc BTSG $57.40 $23.87 -58%
Tempus AI, Inc TEM $48.61 $12.67 -74%
HealthEquity, Inc HQY $84.61 $79.57 -6%
M3, Inc MTHRY $5.03 $7.44 +48%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is RHT (RHT) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0340 versus a price of A$0.0460 — about −26% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RHT?
Our model-based fair value for RHT is A$0.0340 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.0460.
What is the quality score of RHT?
RHT has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of RHT (RHT)?
RHT reported trailing-twelve-month revenue of about A$13.8M (latest available figure, as of Jun 26, 2026).
What is the net profit margin of RHT?
The net profit margin of RHT is about 5.6%, meaning it keeps roughly 5.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.